Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib plus FLA chemotherapy in pediatric relapsed/refractory KMT2A-r, NUP98-r, or NPM1-mut AML
NL-OMON59404Phase 2Not yet recruiting
- Sponsor
- Pediatric Research International
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of revumenib in acute myeloid leukemia (AML), sponsored by Pediatric Research International. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON59404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59404.